Related Experiment Video

Updated: May 9, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Design of a novel LOX-1 receptor antagonist mimicking the natural substrate

Mattia Falconi1, Sarah Ciccone, Paola D'Arrigo

  • 1Department of Biology, Interuniversity Consortium, National Institute Biostructure and Biosystem (INBB), University of Rome "Tor Vergata", Via della Ricerca Scientifica 1, 00133, Rome, Italy. falconi@uniroma2.it

Biochemical and Biophysical Research Communications
|July 30, 2013
PubMed

Insights

Researchers developed PLAzPC, a novel compound that effectively inhibits oxidized low-density lipoprotein (ox-LDL) binding to the LOX-1 receptor. This breakthrough offers a promising therapeutic strategy for atherosclerosis and inflammation by targeting key molecular interactions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a key mediator in atherosclerosis, primarily expressed in endothelial cells and upregulated in atherosclerotic lesions.
  • Overexpression of LOX-1 contributes to inflammatory processes, highlighting the urgent need for specific inhibitors to mitigate disease progression.

Purpose of the Study:

  • To design and synthesize a novel modified oxidized phospholipid, PLAzPC, capable of inhibiting the interaction between oxidized low-density lipoprotein (ox-LDL) and the LOX-1 receptor.
  • To investigate the molecular mechanism by which PLAzPC interferes with ox-LDL binding to LOX-1.
  • To evaluate the efficacy of PLAzPC as an inhibitor of ox-LDL binding compared to existing agents.

Main Methods:

  • Molecular docking simulations were employed to predict the binding mode of PLAzPC within the LOX-1 receptor's recognition domain.
  • Synthesis of the novel modified oxidized phospholipid, PLAzPC.
  • In vitro binding assays using a cell model expressing human LOX-1 receptors to quantify the inhibition of ox-LDL binding by PLAzPC.

Main Results:

  • Molecular docking revealed that PLAzPC disrupts the hydrophobic interactions crucial for ox-LDL recognition by LOX-1, instead facilitating interactions with charged residues.
  • PLAzPC effectively inhibited the binding of ox-LDL to LOX-1 in a cellular model.
  • The inhibitory efficacy of PLAzPC was found to be superior to previously identified inhibitors of the ox-LDL/LOX-1 pathway.

Conclusions:

  • PLAzPC represents a novel and highly effective inhibitor of the LOX-1 receptor.
  • The unique binding mechanism of PLAzPC offers a promising therapeutic avenue for managing atherosclerosis and associated inflammatory conditions.
  • Further development of PLAzPC could lead to new treatments for cardiovascular diseases driven by LOX-1 activation.
Keywords:
1,1′-dioctadecyl-3,3,3′,3′-tetramethyllindocarbocyanine perchlorate1-hydroxybenzotriazoleAtherosclerosisC-type lectin-like domainCTLDCell-based assayDiIHOBtLDLLOX-1LOX-1 inhibitorMolecular dockingOxidized phospholipidsSRBlectin-like oxidized low-density lipoprotein receptor-1low-density lipoproteinox-LDLoxidized low-density lipoproteinsulforhodamine B

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: